Abcellera Biologics Inc is trading 6.8% down today at $5.93 as the stock undergoes consolidation following a significant multi-day rally.
- The recent surge was driven by a Q1 2026 earnings beat and positive interim Phase 1 data for the company's ABCL635 program.
- Shares jumped double digits on June 4, 2026, ahead of a presentation at the Jefferies Global Healthcare Conference.
- Today's price action is viewed as short-term profit taking rather than a reaction to new company-specific news.